nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Acute phase treatment in central retinal artery occlusion: thrombolysis, hyperbaric oxygen therapy or both?
|
Ferreira, Daniel |
|
|
50 |
4 |
p. 984-988 |
artikel |
2 |
Albumin and bleed risk in rivaroxaban treated patients
|
Wojakowski, E. |
|
|
50 |
4 |
p. 1004-1011 |
artikel |
3 |
Argatroban therapy for heparin-induced thrombocytopenia in a patient with coronavirus disease 2019
|
Ogawa, Yoshihiko |
|
|
50 |
4 |
p. 1012-1014 |
artikel |
4 |
Assessment of the attitude, awareness and practice of periprocedural warfarin management among health care professional in Qatar. A cross sectional survey
|
Eljilany, Islam |
|
|
50 |
4 |
p. 957-968 |
artikel |
5 |
A stricter control of low-density lipoprotein is necessary for thrombosis reduction in “lower thrombosis risk” patients with atrial fibrillation: a multicenter retrospective cohort study
|
Liu, Weizhuo |
|
|
50 |
4 |
p. 849-857 |
artikel |
6 |
Bleeding prevalence in COVID-19 patients receiving intensive antithrombotic prophylaxis
|
Kessler, Chiara |
|
|
50 |
4 |
p. 833-836 |
artikel |
7 |
Clinical significance of healed plaque detected by optical coherence tomography: a 2-year follow-up study
|
Kurihara, Osamu |
|
|
50 |
4 |
p. 895-902 |
artikel |
8 |
Concerns for management of STEMI patients in the COVID-19 era: a paradox phenomenon
|
Vlachakis, Panayotis K. |
|
|
50 |
4 |
p. 809-813 |
artikel |
9 |
Differentiating biochemical from clinical heparin resistance in COVID-19
|
Lisman, Ton |
|
|
50 |
4 |
p. 1015-1016 |
artikel |
10 |
Drug-induced disseminated intravascular coagulation: a pharmacovigilance study on World Health Organization’s database
|
Bonaldo, Giulia |
|
|
50 |
4 |
p. 763-771 |
artikel |
11 |
Effect of erroneous body-weight estimation on outcome of thrombolyzed stroke patients
|
Paliwal, Prakash R. |
|
|
50 |
4 |
p. 921-928 |
artikel |
12 |
Efficacy and safety of low dose rivaroxaban in patients with coronary heart disease: a systematic review and meta-analysis
|
Khan, Safi U. |
|
|
50 |
4 |
p. 913-920 |
artikel |
13 |
Experience of a 40-day (6 week) LMWH treatment for isolated distal deep vein thrombosis
|
Asonitis, Konstantinos |
|
|
50 |
4 |
p. 837-843 |
artikel |
14 |
How haemophilia A impacts severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) treatment: a case report
|
Zanon, Ezio |
|
|
50 |
4 |
p. 795-798 |
artikel |
15 |
Implementation of automatic data extraction from an enterprise database warehouse (EDW) for validating pediatric VTE decision rule: a prospective observational study in a critical care population
|
Schultz, Rachael F. |
|
|
50 |
4 |
p. 782-789 |
artikel |
16 |
Inflammatory markers in thrombosis associated with primary antiphospholipid syndrome
|
Arantes, Fernanda T. |
|
|
50 |
4 |
p. 772-781 |
artikel |
17 |
In vivo demonstration of microvascular thrombosis in severe COVID-19
|
do Espírito Santo, Douglas Alexandre |
|
|
50 |
4 |
p. 790-794 |
artikel |
18 |
Long lasting hypercoagulability after subclinical COVID-19
|
Ferroli, Paolo |
|
|
50 |
4 |
p. 822-824 |
artikel |
19 |
Loop-mediated isothermal amplification (LAMP)-based method for detecting factor V Leiden and factor II G20210A common variants
|
Luca Tiscia, Giovanni |
|
|
50 |
4 |
p. 908-912 |
artikel |
20 |
Low prevalence of JAK2 V617F mutation in patients with thrombosis and normal blood counts: a retrospective impact study
|
Levraut, Michaël |
|
|
50 |
4 |
p. 995-1003 |
artikel |
21 |
Predictors for layered coronary plaques: an optical coherence tomography study
|
Araki, Makoto |
|
|
50 |
4 |
p. 886-894 |
artikel |
22 |
Prominent coagulation disorder is closely related to inflammatory response and could be as a prognostic indicator for ICU patients with COVID-19
|
Liu, Yang |
|
|
50 |
4 |
p. 825-832 |
artikel |
23 |
Residual platelet reactivity, thrombus burden and myocardial reperfusion in patients treated by PCI after successful pre-hospital fibrinolysis compared to primary PCI
|
Roule, Vincent |
|
|
50 |
4 |
p. 858-866 |
artikel |
24 |
Risk Of Thrombosis In Elderly Immune Primary Trombocytopenic Patients Treated with Thrombopoietin Receptors Agonists
|
Castelli, Roberto |
|
|
50 |
4 |
p. 903-907 |
artikel |
25 |
Rivaroxaban-induced hemorrhagic pericardial tamponade in end-stage renal disease
|
Rapista, Nicole |
|
|
50 |
4 |
p. 982-983 |
artikel |
26 |
Safety and efficacy of short-term (1 to 3 months) dual antiplatelet therapy in patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials
|
Kheiri, Babikir |
|
|
50 |
4 |
p. 867-873 |
artikel |
27 |
Severe high-molecular-weight kininogen deficiency due to a homozygous c.1456C > T nonsense variant in a large Chinese family
|
Yang, Jing |
|
|
50 |
4 |
p. 989-994 |
artikel |
28 |
The Impact of platelet–fibrin clot strength on occurrence and clinical outcomes of peripheral artery disease in patients with significant coronary artery disease
|
Bae, Jae Seok |
|
|
50 |
4 |
p. 969-981 |
artikel |
29 |
The role of P2Y12 receptor inhibition in ischemic stroke on microglia, platelets and vascular smooth muscle cells
|
Li, Fengyang |
|
|
50 |
4 |
p. 874-885 |
artikel |
30 |
Thrombolysis in massive and submassive pulmonary embolism during pregnancy and the puerperium: a systematic review
|
Rodriguez, David |
|
|
50 |
4 |
p. 929-941 |
artikel |
31 |
Thromboprophylaxis: balancing evidence and experience during the COVID-19 pandemic
|
Marchandot, Benjamin |
|
|
50 |
4 |
p. 799-808 |
artikel |
32 |
Ticagrelor for the primary prevention of stroke in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials
|
Kong, Qi |
|
|
50 |
4 |
p. 942-956 |
artikel |
33 |
Use of apixaban and rivaroxaban in young adults with acute venous thromboembolism: a multi-center retrospective case series
|
DeCamillo, Deborah |
|
|
50 |
4 |
p. 844-848 |
artikel |
34 |
Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review and meta-analysis
|
Hasan, Syed Shahzad |
|
|
50 |
4 |
p. 814-821 |
artikel |